The United States is failing to integrate hepatitis C screening and treatment into drug treatment centers, despite having a population at high risk for the virus. Alison Starkie, an intervention worker at a drug treatment service in Manchester, documents the struggle of reaching vulnerable populations, particularly those experiencing homelessness or active substance use.
Drug treatment centers represent an obvious access point for hepatitis C interventions. People undergoing addiction treatment have elevated infection rates and regular contact with healthcare providers. Yet most U.S. treatment facilities lack protocols for hepatitis C screening or the resources to connect patients with antiretroviral therapy.
The oversight reflects a fragmented healthcare system where addiction services operate separately from hepatitis C elimination efforts. Federal agencies have pursued hepatitis C eradication goals without adequately funding integration at the local level. Treatment centers struggle with staffing shortages and budget constraints. Adding hepatitis C services requires training, equipment, and coordination with specialists.
Britain's National Health Service takes a different approach. Intervention workers embedded in drug services proactively identify and treat hepatitis C cases. This model achieves higher cure rates among vulnerable populations compared to U.S. approaches that rely on patients seeking specialty care.
The policy gap carries public health consequences. Undiagnosed hepatitis C progresses to cirrhosis and liver cancer. Untreated individuals continue transmitting the virus. Modern direct-acting antiviral drugs cure hepatitis C in eight to twelve weeks with minimal side effects, making treatment feasible in lower-barrier settings.
Closing this gap requires federal funding to equip drug treatment centers with screening capacity and clinical partnerships. The Centers for Disease Control and Prevention and the Health Resources and Services Administration could establish standards and resources for integrated care. State Medicaid programs could reimburse treatment centers for hepatitis C services.
The infrastructure exists. The political will to fund integration has lagged. Without deliberate policy change